Medtronic Just Posted Its Best Quarter in 2.5 Years

Core Insights - Medtronic reported its strongest revenue growth in 10 quarters, achieving 8.7% reported growth and 6.0% organic growth for Q3 fiscal 2026, surpassing Wall Street expectations with revenue of $9.02 billion and non-GAAP EPS of $1.36 [1] Revenue Performance - The Cardiovascular Portfolio led the growth with 13.8% reported growth, driven by an 80% increase in Cardiac Ablation Solutions [1] - U.S. cardiac ablation revenue surged 137%, primarily due to the pulsed field ablation portfolio [1] - Cardiac Rhythm & Heart Failure revenue reached $1.86 billion, up 17%, while Diabetes segment posted 8.3% organic growth to $796 million [1] Regulatory and M&A Developments - Medtronic achieved significant regulatory milestones, including CE Mark approval for Sphere-360 and FDA clearance for the Hugo robotic-assisted surgery system, with initial cases completed in February 2026 [1] - The company also secured FDA clearance for the Stealth AXiS spinal system and made strategic acquisitions, including CathWorks and an investment in Anteris [1] Profitability and Future Outlook - Non-GAAP operating profit was $2.18 billion with a 24.1% margin, although GAAP net income declined 11.67% year-over-year to $1.14 billion [1] - Management reiterated full-year guidance for approximately 5.5% organic growth and EPS of $5.62 to $5.66, which includes a $185 million tariff impact [1]